2020 Trends In Pharma Asset Licensing And Deal Terms: A Survey Of Key Decision-Makers Lain Anderson TJ Bilodeau Read more
Related Practice Life Sciences & Pharma In this article, we describe some key drivers of asset value, as well as areas of alignment and divergence between parties on deal expectations. 01052021090143
Executive Insights Life Sciences & Pharma First vs. Best in Class — Simplifying the Equation for Biopharma June 27, 2024
Executive Insights Diagnostics, Tools and Personalized Medicine Commercial Excellence in Life Sciences Tools and Services Companies April 8, 2024
Executive Insights Biotech and Pharmaceuticals Variability in Large Pharma Launch Performance January 16, 2024
Executive Insights Business Services Benefits of the 4-Day Week: The Jury Is Still Out October 31, 2023
Article Digital AI Has Moved Beyond Hype — It Is Driving Performance and Deployment Is Widespread September 20, 2023